Eric Shaff, Seres CEO

Nestlé is bet­ting $525M on a bid to pi­o­neer world's first mi­cro­bio­me drug

Af­ter fight­ing a years-long up­hill bat­tle with its oral mi­cro­bio­me can­di­date SER-109, Seres Ther­a­peu­tics fi­nal­ly got the Phase III re­sults it was look­ing for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.